Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Carmat |
| Country | France |
| Start Date | Oct 01, 2022 |
| End Date | Jun 30, 2025 |
| Duration | 1,003 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190185733 |
At Carmat we have designed and developed Aeson®, the world’s most advanced total artificial heart (TAH), aiming to fulfill an unmet medical need by providing a credible therapeutic alternative to heart transplants for people suffering from end-stage biventricular heart failure.
Aeson® is an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The device is electro-hydraulically driven with a shape close to that of a human heart.
Once the Aeson® is powered, it mimics the action of a normal heart, providing mechanical circulatory support and restoring normal blood flow through the body.Aeson® differs from other existing artificial hearts (or TAH – total artificial hearts) in its unique combination of three features: pulsatility, autoregulation and hemocompatibility.
With Aeson®, Carmat is creating a new therapeutic class of “physiologic heart replacement therapy” (PHRT).
Carmat
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant